The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BDSX | -71.43% | -96.47% | -48.72% | -97% |
| S&P | +13.19% | +87.83% | +13.42% | +106% |
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
No news articles found for Biodesix.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $21.77M | 19.9% |
| Gross Profit | $17.66M | 26.4% |
| Gross Margin | 81.14% | 4.2% |
| Market Cap | $60.40M | -76.7% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 273 | 25.8% |
| Net Income | -$8.72M | 15.0% |
| EBITDA | -$5.67M | 21.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.70M | -47.0% |
| Accounts Receivable | $12.67M | 57.7% |
| Inventory | 1.4 | 16.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $71.52M | 16.7% |
| Short Term Debt | $1.41M | 115.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.30% | 4.9% |
| Return On Invested Capital | -92.27% | -13.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.93M | 18.1% |
| Operating Free Cash Flow | -$8.88M | 16.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 10.66 | 8.28 | 36.35 | 48.63 | 423.14% |
| Price to Sales | 3.14 | 1.23 | 0.54 | 0.71 | -82.22% |
| Price to Tangible Book Value | 696.82 | -62731.95 | -88.58 | -2.95 | -100.36% |
| Enterprise Value to EBITDA | -50.49 | -17.79 | -11.19 | -19.92 | -50.87% |
| Return on Equity | -337.3% | -1454.4% | -219.7% | -302.6% | -8.82% |
| Total Debt | $61.98M | $62.29M | $72.14M | $72.93M | 17.71% |
No podcast episodes available.
BDSX earnings call for the period ending June 30, 2022.
BDSX earnings call for the period ending March 31, 2022.
BDSX earnings call for the period ending December 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
